ORION CORPORATION PRESS RELEASE 20 NOVEMBER 2023 at 15.00 EET                       Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution) Orion Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Bonqat® (pregabalin oral solution) for alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats.

ORION CORPORATION新闻稿2023年11月20日15.00 EET ORION Animal Health获得FDA批准Bonqat®（普瑞巴林口服液）ORION CORPORATION今天宣布美国食品和药物管理局（FDA）已批准Bonqat®（普瑞巴林口服液）用于缓解与之相关的急性焦虑和恐惧猫的运输和兽医访问。

Pregabalin is a new active substance for veterinary use and it acts in the central nervous system by reducing the release of various neurotransmitters (glutamate and monoaminergic neurotransmitters), resulting in an anxiolytic effect. Orion’s long-standing strategic partner, Zoetis, has the exclusive right to market and sell Bonqat in the United States.

普瑞巴林是一种用于兽医的新型活性物质，它通过减少各种神经递质（谷氨酸和单胺能神经递质）的释放而在中枢神经系统中起作用，从而产生抗焦虑作用。Orion的长期战略合作伙伴Zoetis拥有在美国销售和销售Bonqat的专有权。

Bonqat is anticipated to be available in the U.S. by mid-2024. About OrionOrion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products.

预计到2024年中期，Bonqat将在美国上市。关于OrionOrion是一家全球性的芬兰制药公司-一家幸福的建造者。我们开发，制造和销售人类和兽药以及活性药物成分。Orion拥有广泛的专有和仿制药以及自我保健产品组合。

The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year.

我们药物研发的核心治疗领域是肿瘤学和疼痛。Orion开发的专有产品用于治疗癌症，神经系统疾病和呼吸系统疾病等。Orion在2022年的净销售额为1.34亿欧元，截至年底该公司约有3500名员工。

Orion's A and B shares are listed on Nasdaq Helsinki. About ZoetisAs the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stan.

Orion的A和B股在纳斯达克赫尔辛基上市。关于Zoetis作为世界领先的动物健康公司，Zoetis的驱动目标是：通过推进对动物的关怀来培育我们的世界和人类。在创新了70多年来预测，预防，检测和治疗动物疾病的方法之后，Zoetis继续坚持。